BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alex Straumann  ¹     Alfredo J. Lucendo  ²     Stephan Miehlke  ³     Michael Vieth  ⁴     Christoph Schlag  ⁵     Luc Biedermann  ⁶     Cecilio Santander  ⁷     Christoph Schmöcker  ⁸     Ahmed Madisch  ⁹     Jamal Hayat  ¹⁰     Arjan Bredenoord  ¹¹     Stefan Schubert  ¹²     Ralph Mueller  ¹³     Roland Greinwald  ¹³     Alain M. Schoepfer  ¹⁴     Stephen E. Attwood  ¹⁵     Petr Hruz  ¹⁶     Constanza Ciriza De Los Ríos  ¹⁷     Ulrike von Arnim  ^18    
1 Swiss EoE Research Network, Olten, Switzerland
² Hospital General de Tomelloso, Tomelloso, Spain
³ Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany
⁴ Klinikum Bayreuth, Bayreuth, Germany
⁵ Klinikum rechts der Isar - TU München, München, Germany
⁶ University Hospital Zurich, Zurich, Switzerland
⁷ Hospital Universitario de la Princesa, Madrid, Spain
⁸ Sana Klinikum Lichtenberg, Berlin, Germany
⁹ CRH Clinic Hannover, Hannover, Germany
¹⁰ St. George`s University Hospitals NHS Trust, London, United Kingdom
¹¹ Academisch Med. Centrum Amsterdam, Amsterdam, Netherlands
¹² Gastroenterologist in Private Practice, Berlin, Germany
¹³ Dr. Falk Pharma GmbH, Freiburg, Germany
¹⁴ University Hospital (CHUV), Lausanne, Switzerland
¹⁵ Durham University, North Tyneside, United Kingdom
¹⁶ University Hospital Basel, Basel, Switzerland
¹⁷ Hospital 12 de Octubre, Madrid, Spain
¹⁸ University Hospital Magdeburg, Madgeburg, Germany

Session
Novel insights in a new disease: Eosinophilic oesophagitis

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)